Stay updated on Pembrolizumab in Untreated Extensive SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.

Latest updates to the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page
- Check4 days agoChange DetectedAdded the keyword 'Small cell lung carcinoma' and a new 'resources' section linking to the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedRevision history updated to include v3.5.0 and remove v3.4.3. This is a minor metadata update that does not affect study content or results.SummaryDifference0.0%

- Check26 days agoChange DetectedRevision: v3.4.3 added in the page header, replacing Revision: v3.4.2.SummaryDifference0.0%

- Check54 days agoChange DetectedThe page now displays Revision: v3.4.2, and a government funding/operating status notice and the earlier Revision: v3.4.1 were removed; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check61 days agoChange DetectedAdded a site-wide notice about government funding lapse and NIH operating status. Updated the page to version v3.4.1.SummaryDifference0.4%

- Check69 days agoChange DetectedMinor UI and metadata updates: glossary display option added and footer text updated to include 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', replacing the previous labels.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Untreated Extensive SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.